Literature DB >> 21538354

Functional characterization of rat plasma membrane monoamine transporter in the blood-brain and blood-cerebrospinal fluid barriers.

Takashi Okura1, Sayaka Kato, Yusuke Takano, Takenori Sato, Atsushi Yamashita, Riyo Morimoto, Sumio Ohtsuki, Tetsuya Terasaki, Yoshiharu Deguchi.   

Abstract

This study investigated the expression and functional roles of rat plasma membrane monoamine transporter (rPMAT) in the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier by using in vitro brain barrier model cells (TR-BBB13 and TR-CSFB3 cells) and multiple in vivo experimental techniques. Quantitative reverse transcription-polymerase chain reaction analysis showed relatively high expression of rPMAT mRNA in TR-BBB13 and TR-CSFB3 cells. 1-Methyl-4-phenylpyridinium (MPP(+) ) was transported into rPMAT-expressing cells in a sodium-independent manner. [(3) H]MPP(+) was taken up concentration dependently by TR-BBB13 and TR-CSFB3 cells with K(m) values similar to that of rPMAT-expressing cells. [(3) H]MPP(+) transports into these cells were markedly inhibited by serotonin, dopamine, and cationic drugs. rPMAT small interfering RNA (siRNA) significantly suppressed the [(3) H]MPP(+) uptake by TR-BBB13 cells. Intracerebrally injected [(3) H]MPP(+) was eliminated from the brain parenchymal region, whereas brain [(3) H]MPP(+) uptake did not increase with time during in situ brain perfusion, suggesting that the brain-to-blood transport across the BBB predominates over the blood-to-brain transport. Brain microdialysis studies revealed that the elimination across the BBB was significantly decreased by coperfusion of unlabelled MPP(+) , serotonin, or dopamine. [(3) H]MPP(+) was also eliminated from the CSF. These findings suggest that PMAT in brain barriers functions as the brain-to-blood transporter to regulate brain concentrations of organic cations including monoamines and cationic neurotoxins.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21538354     DOI: 10.1002/jps.22594

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  15 in total

1.  Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.

Authors:  Shiro Itagaki; Vadivel Ganapathy; Horace T B Ho; Mingyan Zhou; Ellappan Babu; Joanne Wang
Journal:  Drug Metab Dispos       Date:  2012-03-06       Impact factor: 3.922

2.  The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family.

Authors:  Joao N Dos Santos Pereira; Sina Tadjerpisheh; Manar Abu Abed; Ali R Saadatmand; Babette Weksler; Ignacio A Romero; Pierre-Olivier Couraud; Jürgen Brockmöller; Mladen V Tzvetkov
Journal:  AAPS J       Date:  2014-08-26       Impact factor: 4.009

3.  Constitutive plasma membrane monoamine transporter (PMAT, Slc29a4) deficiency subtly affects anxiety-like and coping behaviours.

Authors:  T Lee Gilman; Christina M George; Melissa Vitela; Myrna Herrera-Rosales; Mohamed S Basiouny; Wouter Koek; Lynette C Daws
Journal:  Eur J Neurosci       Date:  2018-05-24       Impact factor: 3.386

4.  Interspecies comparison of the functional characteristics of plasma membrane monoamine transporter (PMAT) between human, rat and mouse.

Authors:  Yoshiyuki Shirasaka; Nora Lee; Haichuan Duan; Horace Ho; Joanna Pak; Joanne Wang
Journal:  J Chem Neuroanat       Date:  2016-09-15       Impact factor: 3.052

5.  Impaired monoamine and organic cation uptake in choroid plexus in mice with targeted disruption of the plasma membrane monoamine transporter (Slc29a4) gene.

Authors:  Haichuan Duan; Joanne Wang
Journal:  J Biol Chem       Date:  2012-12-19       Impact factor: 5.157

Review 6.  The plasma membrane monoamine transporter (PMAT): Structure, function, and role in organic cation disposition.

Authors:  J Wang
Journal:  Clin Pharmacol Ther       Date:  2016-09-19       Impact factor: 6.875

7.  Transport of biogenic amine neurotransmitters at the mouse blood-retina and blood-brain barriers by uptake1 and uptake2.

Authors:  Pascal André; Bruno Saubaméa; Véronique Cochois-Guégan; Cynthia Marie-Claire; Julie Cattelotte; Maria Smirnova; Alfred H Schinkel; Jean-Michel Scherrmann; Salvatore Cisternino
Journal:  J Cereb Blood Flow Metab       Date:  2012-08-01       Impact factor: 6.200

8.  Brain Distribution of Drugs: Pharmacokinetic Considerations.

Authors:  Irena Loryan; Margareta Hammarlund-Udenaes; Stina Syvänen
Journal:  Handb Exp Pharmacol       Date:  2022

9.  Differences in Cerebral Distribution between Imipramine and Paroxetine via Membrane Transporters at the Rat Blood-Brain Barrier.

Authors:  Shin-Ichi Akanuma; Myeongrae Han; Yuka Murayama; Yoshiyuki Kubo; Ken-Ichi Hosoya
Journal:  Pharm Res       Date:  2022-02-02       Impact factor: 4.200

10.  Expression Profiling of Solute Carrier Gene Families at the Blood-CSF Barrier.

Authors:  Horace T B Ho; Amber Dahlin; Joanne Wang
Journal:  Front Pharmacol       Date:  2012-08-24       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.